Regulatory Strategy for Medical Devices & IVD

Most regulatory delays trace back to one missing step: a strategy that was never written down. Companies start designing a device or assay before classification, conformity route, and target markets are settled, and the gaps surface later, when they're expensive to fix. A regulatory strategy is the plan that settles those decisions early and keeps clinical, quality, and regulatory work pointed at one submission pathway instead of three.

What is a medical device and IVD regulatory strategy?

A medical device or IVD regulatory strategy sets a product's classification, conformity route, target markets, and evidence requirements before development locks those decisions in. It aligns clinical, quality, and regulatory work toward one submission pathway, rather than leaving each function to solve the problem separately once a gap surfaces late.

How is this different from dossier submission or market access support?

Regulatory strategy comes first: classification, conformity route, and country sequencing, before a device is built or a file assembled. Dossier Submission Support takes over once that direction is set, compiling and submitting the technical file itself. Global Market Access extends the same strategy into country-by-country registration once the core pathway is defined.

What goes wrong without a dedicated strategy?

Without a defined strategy, MedTech and IVD companies typically discover the wrong conformity route, a missing standard, or an under-scoped clinical plan only after development is already underway. By then the fixes are expensive: redesigns, added testing, and delayed submissions, rather than a routine mid-course correction.

• Applying the wrong conformity assessment route for the device's class
• Missing applicable regulations, standards, or country-specific requirements
• A clinical or performance evaluation that doesn't match the intended use
• Incomplete technical documentation surfacing for the first time at Notified Body review
• Country launches delayed because market access wasn't planned alongside the core submission

How does Qserve build your regulatory strategy?

We work in three phases, in this order, because each one changes what the next needs to solve.

Classification and gap assessment

We confirm your device or IVD's classification under MDR Annex VIII and IVDR Annex VIII, or the relevant FDA product code, and assess what documentation already exists against what your target markets actually require.

Pathway and roadmap design

We define the conformity route, the evidence plan, and the agency engagement plan, a structured dialogue with a Notified Body, an FDA pre-submission, and sequence your target countries so the roadmap reflects your real launch order, not a generic one.

Execution support

As you build toward submission, we keep the product, clinical, and documentation work aligned to the roadmap, and adjust it as guidance changes, rather than leaving that alignment to whoever notices the drift first.

When should you build or revisit your regulatory strategy?

A regulatory strategy earns its cost at specific points, not as a one-time exercise:

• Early in product design, before the classification and conformity route are locked in
• When redesigning or updating a device whose classification or applicable standards may have changed
• Ahead of a first launch or an expansion into new countries or regions
• During a multi-product portfolio review, ahead of MDR/IVDR recertification or a new target market
• When developing a Companion Diagnostic, combination device, or AI-based product with intersecting regulatory pathways
• When evaluating a medical device or IVD business for acquisition, where regulatory due diligence needs to price in the regulatory risk